The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.本發明之特徵為用於治療HCV之無干擾素療法。該治療較佳歷經較短之持續時間,諸如不超過12週。在一個態樣中,該等療法包含向感染HCV之個體投與至少兩種直接作用抗病毒劑及病毒唑。舉例而言,該等療法包含向該個體投與有效量之治療劑1、治療劑2(或治療劑3)、細胞色素P450抑制劑(例如利托那韋)及病毒唑。